Report results of the Phase 3 REACH 3 trial in chronic GVHD
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 5 May 2020
- Due
- 31 Dec 2020
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“The Phase 3 REACH 3 trial of ruxolitinib versus BAT in patients with steroid-refractory chronic GVHD has completed recruitment and results are expected in the second half of 2020.”
What we found
Evidence strength A What the grades mean
REACH3 results were announced in December 2020, within the second-half 2020 window, and presented at ASH 2020. The exact day is not stated.
-
A Incyte 8-K filed 2021-02-09
“based on data from the successful results of the REACH3 trial, which were presented at ASH 2020.” ✓ confirmed on the page
-
A Incyte 10-K filed 2021-02-09
“Additional data announced in December 2020 showed that best overall response (BOR) rate, defined as any response up to week 24, was achieved in a significantly higher percentage of patients with ruxolitinib therapy compared to BAT.” ✓ confirmed on the page
Market reaction: the shares moved -9.3% against the S&P 500 over the three sessions around the disclosure (8 Feb 2021 to 11 Feb 2021). What this measures
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- REACH 3 Phase 3 trial results in steroid-refractory chronic GVHD
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Incyte? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2020-INCY-005672 · Corrections policy